Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.

Abstract: The present disclosure relates to a ferromagnetic substance containing a crystal of a metal complex molecule in which a heterocycle is bonded to metal, the metal of the metal complex molecule is bonded to the metal of another metal complex via oxygen as a electron donor, and the ferromagnetic substance has a ferromagnetic property balanced with stability of crystals based on a metal-electron donor-metal bond angle that is from 130° to 160°. The present disclosure also relates to a drug containing, as a principal component, the crystal of the metal complex molecule.

Abstract: A metal-salen complex compound responsive drug, which has an antidotal property capable of neutralizing cytotoxicity of a metal-salen complex compound, and an intra-corporeal behavior control system for the metal-salen complex compound are provided. This metal-salen complex compound responsive drug contains an effective amount of a metal chelating agent to suppress side effects by the metal-salen complex compound.

Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.

Abstract: A new radical inhibitor, a composition containing the new radical inhibitor, and a radical generation inhibition method using the new radical inhibitor are provided. A radical inhibitor according to the present invention contains a salen complex compound of a bivalent metal.

Abstract: Provided are an elastic three-dimensional tissue and a method by which the tissue can be produced. The elastic three-dimensional tissue includes smooth muscle cells and an extracellular matrix component, with the smooth muscle cells being layered with the extracellular matrix component interposed therebetween. Furthermore, the production method for a three-dimensional tissue includes layering smooth muscle cells with an extracellular matrix component interposed therebetween, wherein the smooth muscle cells are those directed towards a differentiated type from an undifferentiated type.

Abstract: A battery pack (30) is configured to couple to a power tool (10) by sliding in a sliding direction and it contains a plurality of cells (31). A pair of battery-side, electric-power terminals (312a, 312b, 314a, 314b) and a battery-side signal terminal (313) can be electrically connected to a pair of tool-side, power-supply terminals (212, 214) and a tool-side signal terminal (213), respectively, which are provided on the power tool (10). The pair of battery-side, electric-power terminals (312a, 312b, 314a, 314b) and the battery-side signal terminal (313) are disposed in parallel adjacently in a direction that intersects the sliding direction.

Abstract: A water-tree resistance evaluation material including: a material selection selecting a candidate insulation material; a test carrying out a water tree test on a test piece having electrode holes formed on a first surface; and a candidate insulation material evaluation evaluating characteristics of the candidate insulation material, including progress and speed of a water tree. The test includes: a system and condition setting for setting a test system; a voltage application for grounding a ground-side electrode that is immersed in the ground-side aqueous solution, while applying an AC voltage to an application-side electrode that is immersed in the application-side aqueous solution; a measurement step; and a period determination for determining whether a test period has exceeded a predetermined period.

Abstract: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as has been done hitherto.

Abstract: A magnetic body may be suitably applied to a drug delivery system using magnetism. Furthermore, a drug delivery control device allows the magnetic body to be suitably applied to drug delivery. The magnetic body includes a magnet and a cover part attached to an edge of the magnet. The cover part is composed of a material with high magnetic permeability, and a ratio of a length to a radius of the cover part is 10:1 to 7:3. The drug delivery control device includes the magnetic body, a head for supporting the magnetic body and a drive mechanism of the head that causes the head to operate along a projected region formed by the affected area with respect to a surface of a tissue. A magnetic field is applied from the magnetic body to the affected area where a magnetic drug is administered.

Abstract: It is an object of the present invention to extend the usefulness of an iron-salen complex. The present invention is a new fluorochrome material containing Chemical Formula (I) below. However, M is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.

Abstract: A charger in one aspect of the present invention includes: a connecting portion, two protection devices, a charging device, a control device, and a voltage detection device. A first protection device is configured such that its power consumption in a charging inhibited state is lower than that in a charging permitted state. A second protection device is configured such that its power consumption in the permitted state is lower than that in the inhibited state. The control device is configured to respectively set, when the battery is not connected to the connecting portion, the first protection device to the inhibited state and the second protection device to the permitted state, and thereafter switch, when the voltage value of the charging path detected by the voltage detection device is equal to or greater than a predetermined specified voltage value, the second protection device to the inhibited state.

Abstract: [Object] A system capable of designing an optimum administration form of a magnetic drug is provided. [Solution] The system: determines first information about an side-effect-related organ on which a magnetic drug produces a side effect, based on equipment analysis information after administering the magnetic drug (S208); further determines second information about a drug-efficacy-related organ in which drug efficacy of the magnetic drug should be demonstrated (S210); evaluates the administration form of the magnetic drug based on the first information and the second information; corrects the administration form of the magnetic drug based on an evaluation result (S224); and outputs information of the corrected administration form (S226).

Abstract: The present disclosure relates to a ferromagnetic substance containing a crystal of a metal complex molecule in which a heterocycle is bonded to metal, the metal of the metal complex molecule is bonded to the metal of another metal complex via oxygen as a electron donor, and the ferromagnetic substance has a ferromagnetic property balanced with stability of crystals based on a metal—electron donor—metal bond angle that is from 130° to 160°. The present disclosure also relates to a drug containing, as a principal component, the crystal of the metal complex molecule.

Abstract: [Object] A magnetization technique that enhances magnetic properties of an organic compound is provided without damaging properties of the organic compound or while maintaining the structure of the organic compound. [Solution] The present disclosure is a method for manufacturing a magnetic substance composed of crystals of a magnetization target compound and an electron acceptor by combining the magnetization target compound with the electron acceptor; forming a solution by dissolving a mixture of the magnetization target compound and the electron acceptor in a solvent; maintaining the solution in a very low temperature state and allowing the solution to deposit the crystals of the magnetic target compound and the electron acceptor; and separating the crystals from the solvent.

Abstract: The present invention provides a novel compound capable of inhibiting cardiac adenylyl cyclase. The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof: where R1, R2 and R3 each independently represent a hydrogen atom or an acyl group having an acidic or basic substituent, provided that all of R1, R2 and R3 are not simultaneously a hydrogen atom. The present invention also provides a modulator of adenylyl cyclase activity, a pharmaceutical composition and a food composition, all of which comprise the above-described compound or a pharmaceutically acceptable salt, ester or solvate thereof.

Abstract: The present invention provides a metal-salen complex compound having a controlled grain size that enables the metal-salen complex compound to exert its pharmacological effects as a medicine, at a target region. This metal-salen complex compound is composed of the following that has a crystal grain size of 8 ?m or less, and that is represented by the chemical formula below. N,N?-Bis(salicylidene)ethylenediamine metal M is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.

Abstract: A magnetic composition containing a metal-salen complex compound which can be securely guided by a magnetic field to a target area to be preferably treated, and a method for producing the magnetic composition are provided. The magnetic composition is prepared by dispersing magnetic particles, which are obtained by coating a metal-salen complex compound with a dispersant, in a polar solvent by means of the dispersant. Furthermore, the magnetic composition production method includes a first step of mixing the metal-salen complex compound with the dispersant in an organic solvent and coating the metal-salen complex compound with the dispersant and a second step of dispersing the metal-salen complex in a polar solvent.

Abstract: A drug containing a metal-salen complex compound which is effective for a brain tumor is provided. The present invention is an anti-brain-tumor drug containing a metal-salen complex compound represented by the following Chemical Formula (I). In the formula, M represents a metal atom which is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X represents a halogen atom.

Abstract: A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds.